Sodium-glucose cotransporter 2 inhibitor use: A pharmaco-ergonomic qualification tool by Sanjay Kalra, A G Unnikrishnan, Manash Baruah, Pallavi Kawatra, Jignesh Ved

Subjects: Get full text

Sodium–glucose cotransporter 2 inhibitor and sarcopenia in a lean elderly adult with type 2 diabetes: A case report by Megumi Yasuda, Katsumi Iizuka, Takehiro Kato, Yanyan Liu, Ken Takao, Kenta Nonomura, Masami Mizuno, Daisuke Yabe

Subjects: Get full text

Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms by Keming Huang, Xianling Luo, Bin Liao, Guang Li, Jian Feng

Subjects: “…Sodium-glucose cotransporter 2 inhibitor…”
Get full text

Enhancement of the serum chloride concentration by administration of sodium–glucose cotransporter-2 inhibitor and its mechanisms and clinical significance in type 2 diabetic patien... by Hajime Kataoka, Yuichi Yoshida

Subjects: “…Sodium–glucose cotransporter-2 inhibitor…”
Get full text

Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, rando... by Masaya Koshizaka, Ko Ishikawa, Ryoichi Ishibashi, Yoshiro Maezawa, Kenichi Sakamoto, Daigaku Uchida, Susumu Nakamura, Masaya Yamaga, Hidetaka Yokoh, Akina Kobayashi, Shunichiro Onishi, Kazuki Kobayashi, Jun Ogino, Naotake Hashimoto, Hirotake Tokuyama, Fumio Shimada, Emi Ohara, Takahiro Ishikawa, Mayumi Shoji, Shintaro Ide, Kana Ide, Yusuke Baba, Akiko Hattori, Takumi Kitamoto, Takuro Horikoshi, Ryouta Shimofusa, Sho Takahashi, Kengo Nagashima, Yasunori Sato, Minoru Takemoto, L. Kristin Newby, Koutaro Yokote, the PRIME‐V study group

Subjects: Get full text

Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study by Ikuro Matsuba, Takehiro Kawata, Kotaro Iemitsu, Taro Asakura, Hikaru Amemiya, Masashi Ishikawa, Syogo Ito, Mizuki Kaneshiro, Akira Kanamori, Akira Kubota, Kazuaki Shinoda, Masahiko Takai, Tetsuo Takuma, Masahiro Takihata, Hiroshi Takeda, Keiji Tanaka, Yoko Matsuzawa, Hideo Machimura, Fuyuki Minagawa, Nobuaki Minami, Atsuko Mokubo, Masaaki Miyakawa, Yasuo Terauchi, Yasushi Tanaka

Subjects: Get full text

Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta‐Analysis o... by Yao Hao Teo, Yao Neng Teo, Nicholas L. Syn, Cheryl Shumin Kow, Celine Shuen Yin Yoong, Benjamin Y. Q. Tan, Tiong‐Cheng Yeo, Chi‐Hang Lee, Weiqin Lin, Ching‐Hui Sia

Subjects: Get full text

Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure by Akshyaya Pradhan, Shweta Vohra, Pravesh Vishwakarma, Rishi Sethi

Subjects: Get full text

Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin by Aika Miya, Akinobu Nakamura, Kyu Yong Cho, Shinichiro Kawata, Hiroshi Nomoto, So Nagai, Hajime Sugawara, Shinji Taneda, Kazuhisa Tsuchida, Kazuno Omori, Hiroki Yokoyama, Jun Takeuchi, Shin Aoki, Yoshio Kurihara, Tatsuya Atsumi, Hideaki Miyoshi

Subjects: Get full text

SGLT2 inhibitor versus carbohydrate-restricted isocaloric diet: reprogramming substrate oxidation in type 2 diabetes by Hiroyuki Igarashi, Hiroshi Uchino, Momoko Kanaguchi, Kaori Hisanaga, Genki Sato, Fukumi Yoshikawa, Masashi Furuta, Naohiro Washizawa, Shuki Usui, Masahiko Miyagi, Takahisa Hirose

Subjects: “…Sodium/glucose cotransporter-2 inhibitor…”
Get full text

Early detection of euglycemic ketoacidosis during thoracic surgery associated with empagliflozin in a patient with type 2 diabetes: A case report by Chie Kitahara, Shuhei Morita, Shohei Kishimoto, Shohei Matsuno, Shinsuke Uraki, Ken Takeshima, Yasushi Furukawa, Hidefumi Inaba, Hiroshi Iwakura, Hiroyuki Ariyasu, Hiroto Furuta, Masahiro Nishi, Takashi Akamizu

Subjects: Get full text

Safety and efficacy of empagliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post hoc analysis of data from the SACRA study by Kenta Okada, Satoshi Hoshide, Mitsutoshi Kato, Hiroshi Kanegae, Shun Ishibashi, Kazuomi Kario

Subjects: Get full text

Changes in glycemic control and skeletal muscle mass indices after dapagliflozin treatment in individuals with type 1 diabetes mellitus by Yuta Yoshimura, Yoshitaka Hashimoto, Hiroshi Okada, Maya Takegami, Hanako Nakajima, Tomoki Miyoshi, Takashi Yoshimura, Masahiro Yamazaki, Masahide Hamaguchi, Michiaki Fukui

Subjects: Get full text

Canagliflozin, a sodium–glucose cotransporter 2 inhibitor, normalizes renal susceptibility to type 1 cardiorenal syndrome through reduction of renal oxidative stress in diabetic ra... by Yukishige Kimura, Atsushi Kuno, Masaya Tanno, Tatsuya Sato, Kouhei Ohno, Satoru Shibata, Kei Nakata, Hirohito Sugawara, Koki Abe, Yusuke Igaki, Toshiyuki Yano, Takayuki Miki, Tetsuji Miura

Subjects: Get full text

Effect of sodium–glucose cotransporter 2 inhibitor medication on new prescriptions of antihypertensives, antigout/antihyperuricemics and antidyslipidemics in Japan: Analysis using... by Maki Gouda, Kenji Arakawa, Masaya Inagaki, Yoshiteru Ushirogawa

Subjects: Get full text

Sodium-glucose cotransporter 2 inhibitor may not prevent atrial fibrillation in patients with heart failure: a systematic review by Xiaolan Ouyang, Jiafu Wang, Qian Chen, Long Peng, Suhua Li, Xixiang Tang

Subjects: “…Sodium-glucose cotransporter 2 inhibitor…”
Get full text

Current status of diabetes treatment in Miyazaki Prefecture, Japan: Results of a questionnaire survey conducted in 2016 and 2020 by Yudai Uehira, Hiroaki Ueno, Emi Ebihara, Taisuke Uchida, Hiroki Nabekura, Hideyuki Sakoda, Tadato Yonekawa, Hideki Yamaguchi, Masamitsu Nakazato

Subjects: Get full text

The impacts of SGLT2 inhibitors on the mortality of patients with tuberculosis by Chung-Shu Lee, Chung-Han Ho, Kuang-Ming Liao, Yu-Cih Wu, Chin-Chung Shu

Subjects: “…Sodium-glucose cotransporter 2 inhibitors…”
Get full text

Do sodium–glucose cotransporter 2 inhibitors lead to fracture risk? A pharmacovigilance real‐world study by Bin Zhao, Juan Shen, Jun Zhao, Hui Pan

Subjects: Get full text

Balancing Risks and Benefits: Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis by Jan P. Kleinjan, Justin Blom, André P. van Beek, Hjalmar R. Bouma, Peter R. van Dijk

Subjects: “…sodium-glucose cotransporter 2 inhibitors…”
Get full text